Radiotherapy Market

Global Radiotherapy Market Size

The global radiotherapy market is projected to grow from USD 7.73 billion in 2025 to USD 8.20 billion in 2026 and reach USD 13.15 billion by 2034, registering a CAGR of 6.08% during the forecast period from 2026 to 2034.

Radiotherapy is the use of ionizing radiation to target and destroy malignant cells in cancer patients, serving as a cornerstone of oncology treatment across primary, adjuvant, and palliative care settings. Techniques such as external beam radiotherapy (EBRT), intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and brachytherapy are employed to deliver precise doses while minimizing damage to surrounding healthy tissue. As per the World Health Organization, over 50% of all cancer patients require radiotherapy at some point during their treatment, underscoring its clinical indispensability. The International Agency for Research on Cancer points out that approximately 19.3 million new cancer cases were diagnosed globally in 2023, creating sustained demand for advanced radiation modalities. Additionally, the Union for International Cancer Control shows that in low- and middle-income countries, up to 70% of patients present with advanced-stage disease, making radiotherapy a critical intervention for symptom management and survival extension.

MARKET DRIVERS

Rising Global Incidence of Cancer and Expanding Treatment Indications

The escalating burden of cancer worldwide is the most significant driver of demand for radiotherapy services. According to the International Agency for Research on Cancer, the global incidence of cancer is projected to rise to 28.4 million new cases annually by 2040, representing a 47% increase from 2023 levels. This surge is fueled by aging populations, lifestyle changes, and improved detection rates, particularly in breast, prostate, and lung cancers, conditions where radiotherapy plays a pivotal role. The American Society for Radiation Oncology confirms that over 60% of cancer patients in the U.S. receive radiotherapy as part of their treatment plan, with curative intent in early-stage disease and palliative benefits in advanced cases. These epidemiological trends are compelling governments and healthcare providers to expand radiotherapy infrastructure.

Technological Advancements Enhancing Precision and Treatment Efficacy

Innovations in imaging integration, motion management, and dose delivery have significantly improved the accuracy and safety of radiotherapy, driving clinical adoption. As per the European Society for Radiotherapy & Oncology, modern linear accelerators equipped with cone-beam CT and real-time tumor tracking can reduce treatment margins by up to 50%, sparing critical organs in head and neck cancers. Also, the U.S. National Cancer Institute reports that stereotactic body radiotherapy (SBRT) achieves local control rates exceeding 90% in early-stage non-small cell lung cancer, making it a non-surgical alternative for inoperable patients. With over 12,000 IMRT-capable machines installed globally, as documented by the International Atomic Energy Agency (IAEA), technological maturity is enabling broader access to high-precision treatments across diverse healthcare settings.

MARKET RESTRAINTS

Severe Shortage of Radiotherapy Infrastructure in Low- and Middle-Income Countries

The profound disparity in access, particularly in resource-constrained regions, is a critical restraint in the global radiotherapy market. As per the International Atomic Energy Agency, over 50% of countries lack a single radiation therapy machine, and sub-Saharan Africa has only one machine per 5 million people, far below the recommended one per 500,000. As per the World Health Organization, 90% of patients in low-income nations do not receive adequate radiation treatment, leading to preventable mortality. Even in middle-income countries like Pakistan and Bangladesh, machine-to-patient ratios remain critically low, with maintenance challenges and power instability further limiting utilization. This infrastructure deficit undermines cancer control efforts and restricts market expansion in regions with the fastest-growing cancer burdens, despite increasing awareness and demand.

High Cost of Equipment Acquisition, Maintenance, and Skilled Personnel

The financial and human capital required to establish and operate a radiotherapy facility present a significant barrier, especially for public health systems and private clinics in emerging economies. According to the U.S. Government Accountability Office, the acquisition cost of a linear accelerator ranges from $1.5 million to $4 million, with annual maintenance contracts exceeding $200,000. As per the International Atomic Energy Agency, over 30% of radiotherapy machines in Africa are non-functional due to a lack of spare parts and technical expertise. Besides, the global shortage of radiation oncologists and medical physicists is acute; the American Society for Radiation Oncology estimates that sub-Saharan Africa has fewer than 100 board-certified radiation oncologists for 1.3 billion people. Training programs are limited, and retention is poor due to migration to higher-income countries. These economic and workforce constraints hinder the scalability of radiotherapy services, even where political will and patient demand exist.

MARKET OPPORTUNITIES

Integration of Artificial Intelligence in Treatment Planning and Delivery

Artificial intelligence is revolutionizing radiotherapy by accelerating treatment planning, enhancing accuracy, and reducing clinician workload. As per a 2023 study published in Nature Medicine, AI algorithms can generate clinically acceptable radiation plans for head and neck cancers in under 30 seconds, compared to 3–5 hours manually, without compromising dosimetric quality. The University of Pennsylvania’s Abramson Cancer Center reports that AI-driven auto-segmentation reduces contouring time by 70%, improving consistency across tumor and organ delineation. The U.S. Food and Drug Administration has cleared over 20 AI-based radiotherapy software platforms since 2020, including tools for adaptive planning and outcome prediction. So, this convergence is unlocking unprecedented efficiency and personalization in radiation oncology.

Expansion of Radiotherapy Access through Public-Private Partnerships and Global Initiatives

Multilateral efforts to close the global radiotherapy gap are creating new opportunities for technology deployment and service delivery. The International Atomic Energy Agency’s Rays of Hope initiative has supported 40 countries since 2021 with equipment donations, training, and regulatory guidance, aiming to equip one center per participating nation. Besides, mobile radiotherapy units, such as those deployed in rural Australia by the Royal Flying Doctor Service, are proving effective in reaching isolated populations. These collaborative models are not only improving equity but also creating sustainable market pathways for manufacturers and service providers in previously underserved regions.

MARKET CHALLENGES

Regulatory and Safety Challenges in Radiation Delivery

Ensuring the safe and accurate delivery of radiation remains a persistent challenge, with risks of overexposure, underdosing, and equipment malfunction. According to the U.S. Nuclear Regulatory Commission, between 2010 and 2022, over 350 radiotherapy incidents were reported, including 12 cases of severe patient harm due to software errors or incorrect calibration. The World Health Organization’s QUATRO program identifies that 40% of radiotherapy centers in low-income countries lack formal quality assurance protocols, increasing the likelihood of treatment errors. Furthermore, cybersecurity threats to networked treatment systems are emerging; the FDA has issued alerts on vulnerabilities in radiotherapy software that could allow unauthorized access to treatment plans. These safety and regulatory complexities demand rigorous oversight, continuous training, and robust infrastructure, complicating deployment in resource-limited settings.

Workforce Shortages and Training Gaps in Radiation Oncology

The global deficit in trained radiation oncologists, medical physicists, and radiotherapy technologists severely limits service delivery and treatment quality. As per the Global Task Force on Radiotherapy for Cancer Control, an additional 30,000 radiation oncologists are needed worldwide to meet 2030 cancer care targets, with sub-Saharan Africa facing a 95% shortfall. As per the International Atomic Energy Agency, in many African countries, a single oncologist may be responsible for over 1 million people. In Southeast Asia, Indonesia has only 150 radiation oncologists for 270 million citizens, according to the Indonesian Society of Radiation Oncology. Training programs are often underfunded and lack standardized curricula, while retention is challenged by migration to higher-income nations. The European Society for Radiotherapy & Oncology notes that even in Europe, 15% of centers report staffing shortages affecting patient wait times. Without a scalable, well-trained workforce, the expansion of radiotherapy infrastructure cannot translate into equitable patient access.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The Intensity-Modulated Radiation Therapy (IMRT) segment held the largest share of the radiotherapy market by capturing 36.6% of total revenue in 2024. This dominance is driven by its widespread clinical adoption across multiple cancer types due to superior dose conformity and organ-sparing capabilities. IMRT enables precise modulation of radiation beams to match complex tumor shapes, reducing toxicity in critical structures such as the parotid glands in head and neck cancers. According to the U.S. National Cancer Database, over 70% of prostate cancer patients receiving external beam radiotherapy are treated with IMRT, reflecting its standard-of-care status. Besides, the technology’s integration into public healthcare systems, such as the UK’s NHS, showcases its entrenched role in modern oncology practice.

The Stereotactic Body Radiation Therapy (SBRT) segment is expanding at the fastest pace and is projected to grow at a CAGR of 12.8% from 2025 to 2033. This rapid growth is fueled by its efficacy in delivering high, ablative doses in fewer fractions, making it ideal for early-stage tumors and medically inoperable patients. Its application is also expanding into pancreatic, liver, and recurrent cancers, supported by advanced motion management and image guidance, positioning SBRT as a transformative modality in precision oncology.

By Application Insights

The prostate cancer segment is estimated to hold the largest share of the global radiotherapy market during the forecast period. Prostate cancer is prevalent among men. The American Cancer Society says prostate cancer is the second most common cancer among men in the United States and claims a significant number of lives every year. External beam radiation therapy is a popular and effective treatment option for cancer. Factors such as the growing prostate cancer population worldwide, increasing awareness among people regarding the treatment options and screening programs for prostate cancer, and the growing aging population are propelling the growth of the prostate cancer segment. In addition, high accuracy and minimal side effects with radiotherapy to treat prostate cancer are boosting the adoption and contributing to segmental growth.

The breast cancer segment led the radiotherapy market by application and accounted for 23.5% of total treatment procedures in 2024. This lead position is attributed to the high global incidence of breast cancer and the established role of adjuvant radiotherapy in reducing recurrence after lumpectomy. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer worldwide, with 2.3 million new cases annually. The American Society of Clinical Oncology confirms that whole-breast irradiation or partial-breast irradiation is recommended for early-stage patients, with treatment typically delivered over weeks. In Europe, the ESTRO guidelines recommend hypofractionated regimens, which have increased radiotherapy utilization due to shorter treatment duration. Additionally, the rise in breast-conserving surgery has further amplified demand for precise, patient-friendly radiotherapy protocols.

By Equipment Type Insights

The radiation therapy simulators segment is growing at a higher rate and will keep rising during the forecast period. It is frequently used to lower the danger of radiation exposure for medical professionals. New technologies are aiding segment expansion through innovation and development. The market for linear accelerators, which are frequently employed in radiation procedures, accounted for a substantial share of the global market in 2023. As a result, there is a big market need for it. Radiation therapy treatments are now more accurate and precise, thanks in large part to the treatment planning system. Consequently, predicted to rise significantly over the projection period.

REGIONAL ANALYSIS

North America Radiotherapy Market Insights

North America held the most advanced position in the global radiotherapy market by accounting for 33.1% of total revenue in 2024. The region’s lead position is anchored in high healthcare spending, widespread insurance coverage, and a dense network of specialized oncology centers. The United States alone operates about 2,400 radiation therapy facilities, with around 5,000-6,000 linear accelerators installed. Medicare and private insurers widely reimburse advanced modalities such as IMRT, SBRT, and proton therapy, enabling rapid technology adoption. The National Cancer Institute supports over 70 designated cancer centers, driving clinical trials and treatment innovation. Canada has integrated radiotherapy into its universal healthcare system, with provincial agencies ensuring equitable access. With strong R&D investment from companies like Varian (a Siemens Healthineers company) and Elekta, North America remains the epicenter of technological advancement and clinical standardization in radiation oncology.

Europe Radiotherapy Market Insights

Europe holds a significant share of the global radiotherapy market, with a strong emphasis on equitable access and evidence-based protocols. The region benefits from well-established public healthcare systems and cross-national collaboration through organizations like the European Society for Radiotherapy & Oncology (ESTRO). The UK’s National Health Service delivers radiotherapy to over 140,000 patients annually, with a national target of treating 85% of eligible cancer patients. Additionally, the EU’s Horizon Europe program funds AI-driven radiotherapy research, enhancing precision and efficiency. Despite regional disparities, Europe maintains a high standard of care, supported by rigorous training, quality assurance, and patient safety frameworks.

Asia Pacific Radiotherapy Market Insights

Asia Pacific is witnessing the most dynamic growth due to rising cancer incidence and healthcare modernization. China has over 2,000 operational radiotherapy units, with the government aiming to install one per 1 million people by 2030, as per the National Health Commission. India’s Ayushman Bharat program is expanding access to radiation therapy in tier-2 and tier-3 cities, addressing a critical gap where only 30% of patients currently receive treatment, according to the Indian Council of Medical Research. Japan leads in technological adoption, with over 90% of radiotherapy centers equipped for IMRT and SBRT, as noted by the Japanese Society for Radiation Oncology. With increasing public and private investment, the region is rapidly closing the treatment gap.

Latin America Radiotherapy Market Insights

Latin America contributes a notable share to the global radiotherapy market, with Brazil and Mexico leading infrastructure development. Brazil operates over 250 radiotherapy centers, the most in Latin America, supported by the Unified Health System (SUS), which provides free treatment to 75% of cancer patients, according to the Brazilian Ministry of Health. The country has adopted IMRT and SBRT in major urban centers like São Paulo and Rio de Janeiro. Mexico has expanded access through the Instituto Mexicano del Seguro Social (IMSS), which serves millions of people. However, disparities persist. Despite financial constraints, regional initiatives like the IAEA’s Rays of Hope program are supporting equipment donations and training, laying the foundation for equitable service expansion.

Middle East Radiotherapy Market Insights

The Middle East is undergoing rapid transformation in oncology infrastructure. The King Faisal Specialist Hospital in Riyadh operates one of the region’s largest proton therapy facilities, serving patients from across the Gulf. The UAE has achieved near-universal radiotherapy access, with Dubai Healthcare City and Cleveland Clinic Abu Dhabi offering IMRT, SBRT, and brachytherapy. According to the Jordan National Cancer Registry, radiotherapy utilization has doubled since 2015 due to government-funded expansions. With strong political will and international partnerships, the region is emerging as a high-capacity hub for advanced cancer care in the broader MENA region.

KEY MARKET PLAYERS

Nordion Inc. (Canada), RaySearch Laboratories AB (Sweden), Ion Beam Applications SA (Belgium), C. R. Bard Inc. (U.S.), Mevion Medical Systems Inc. (U.S.), Varian Medical Systems Inc. (U.S.), IsoRay Medical Inc. (U.S.), Elekta AB (Sweden), Accuray Incorporated (U.S.) and Mitsubishi Electric Corporation (Japan) are some of the notable companies in the global radiotherapy market.

TOP LEADING PLAYERS IN THE MARKET

Elekta AB

Elekta has established a significant presence in the Asia Pacific radiotherapy market by delivering integrated oncology solutions that combine advanced linear accelerators, treatment planning software, and clinical workflow systems. The company’s Elekta Unity MR-linac, which integrates real-time MRI with radiation delivery, has been deployed in leading cancer centers in Japan, South Korea, and Australia, enabling adaptive radiotherapy for abdominal and pelvic tumors. It expanded its service network in Southeast Asia by establishing technical training hubs in Singapore and Bangkok, ensuring rapid deployment and maintenance support. Elekta also collaborated with the Australian Bragg Centre for Proton Therapy to support clinical implementation of proton therapy. By focusing on precision, connectivity, and clinician-centric design, Elekta continues to influence the evolution of image-guided and adaptive radiation oncology across the region.

Varian Medical Systems

Varian has maintained a dominant technological footprint in the Asia Pacific radiotherapy market through its flagship TrueBeam and Halcyon linear accelerators, widely adopted for high-throughput, precision treatments. The company’s Ethos therapy platform, featuring AI-powered adaptive radiotherapy, has been implemented in major hospitals in Japan, China, and Taiwan, reducing planning time from hours to minutes. It strengthened its presence in India by collaborating with Apollo Hospitals to deploy cloud-based ARIA oncology information systems across 50+ centers. Additionally, Varian’s partnership with the Singapore National Cancer Centre supports research into automated treatment planning for head and neck cancers. With a focus on digital integration, operational efficiency, and scalable solutions, Varian continues to set benchmarks in smart, patient-centered radiotherapy delivery across diverse healthcare environments.

Accuray Incorporated

Accuray has carved a niche in the Asia Pacific market through its CyberKnife and Radixact systems, which specialize in non-invasive, frameless stereotactic radiosurgery and body radiotherapy. The CyberKnife’s robotic delivery platform is particularly valued for treating tumors in challenging locations, such as the spine, pancreas, and liver, without requiring immobilization frames. In Japan, over 60 CyberKnife units are operational, supported by regulatory approval for expanded indications in recurrent cancers, as confirmed by the Pharmaceuticals and Medical Devices Agency (PMDA). By emphasizing extreme precision, minimal invasiveness, and versatility across tumor types, Accuray has positioned itself as a leader in ultra-hypofractionated and outpatient radiotherapy models, gaining traction across urban Asia.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Key players in the radiotherapy market are prioritizing technological differentiation, strategic partnerships, and service ecosystem expansion to solidify their global influence. Companies are investing heavily in AI-driven treatment planning, real-time imaging integration, and adaptive radiotherapy platforms to enhance precision and efficiency. Collaborations with academic medical centers and government health programs are accelerating clinical validation and adoption. Firms are expanding service networks and training academies in emerging markets to ensure operational sustainability. Cloud-based oncology information systems are being leveraged to enable remote monitoring and data analytics. Additionally, companies are pursuing regulatory approvals in high-growth regions and integrating proton therapy and SBRT into comprehensive cancer care pathways, reinforcing their leadership in next-generation radiation oncology.

COMPETITION OVERVIEW

The radiotherapy market features intense technological rivalry among global OEMs, where leadership is determined by innovation in precision, workflow integration, and clinical outcomes rather than price alone. While Elekta, Varian, and Accuray dominate through advanced linacs and specialized platforms, competition is intensifying from regional manufacturers in China and India offering cost-optimized systems. The race to incorporate AI, real-time imaging, and adaptive planning is redefining clinical standards, with companies differentiating through software intelligence and interoperability. Service reliability, training support, and compliance with international safety protocols are becoming critical decision factors for hospitals. Emerging players are leveraging public-private partnerships to penetrate underserved markets, creating a dynamic landscape where technological agility, regulatory strategy, and long-term clinical support define sustainable competitive advantage.

RECENT MARKET DEVELOPMENTS

• In January 2022, Elekta partnered with Tata Memorial Centre in India to integrate AI-based auto-segmentation into radiotherapy planning, enhancing accuracy and reducing clinician workload in high-volume settings.
• In June 2022, Varian launched its ProBeam proton therapy system at Asan Medical Center in South Korea, marking the first commercial installation of its kind in the country and expanding access to advanced particle therapy.
• In September 2022, Accuray designated Bumrungrad International Hospital in Thailand as a regional center of excellence for CyberKnife SBRT, supporting training and clinical adoption across Southeast Asia.
• In March 2023, Elekta inaugurated a technical training hub in Bangkok, equipping service engineers and radiotherapists from across ASEAN countries with hands-on expertise in MR-linac and linac maintenance.
• In November 2023, Varian expanded its ARIA cloud platform deployment with Apollo Hospitals in India, connecting over 50 cancer centers for centralized treatment planning and data management.

MARKET SEGMENTATION

This market research report on the global radiotherapy market has been segmented based on the type, application, equipment and region.

By Type

• External Beam Radiation Therapy
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Image-Guided Radiation Therapy (IGRT)
  • Tomotherapy
  • Stereotactic Radiosurgery
  • Stereotactic Body Radiation Therapy
  • Proton Therapy
• Internal Beam Radiation Therapy
• Systemic Radiation Therapy

By Application

• Skin & Lip Cancer
• Head & Neck Cancer
• Breast Cancer
• Prostate Cancer
• Cervical Cancer
• Lung Cancer
• Spine Cancer

By Equipment Type

• Linear Accelerators
• Radiation Therapy Simulators
• Treatment Planning Systems

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa